Abstract
Objective: To investigate the effect of valproic acid on plasma levels of risperidone and its
active metabolite, 9-hydroxyrisperidone under steady state conditions in 12 schizophrenic
patients.
Methods: The efficacy and tolerability for the combination treatment of valproic acid and
risperidone were examined.
Results: The addition of valproic acid to risperidone significantly reduced total scores of
PANSS positive symptoms, especially excitement and hostility scores, but did not change
SAS scores. Addition of valproic acid did not alter plasma concentrations of risperidone
or 9-hydroxyrisperidone or active moiety, and the risperidone/9-hydroxyrisperidone
ratio. The combination of valproic acid with risperidone decreased plasma levels of
HVA, but not those of MHPG; additionally, treatment with this combination was found
to reduce dopaminergic activity.
Conclusion: These results suggest that the addition of valproic acid to risperidone is both effective
and well tolerated for treating excitement and impulsiveness in schizophrenic patients
without influencing the metabolism of risperidone, and treatment with valproic acid
and risperidone.
References
- 1
Afaq I, Riaz J, Sedky K.
Divalproex as a calmative adjunct for aggressive schizophrenic patients.
J Kentucky Medical Association.
2002;
100
17-22
- 2
Allen MH, Hirschfeld RM, Wozniak PJ, Barker JD, Bowden CL.
Linear relationship of valproate serum concentration to response and optimal serum
levels for acute mania.
Am J Psychiatry.
2006;
163
272-275
- 3
Bai YM, Chen TT, Wu B, Hung CH, Lin WK, Hu TM, Lin CY, Chou P.
A comparative efficacy and safety study of long-acting risperidone injection and risperidone
oral tablets among hospitalized patients: 12-week randomized, single-blind study.
Pharmacopsychiatry.
2006;
39
135-141
- 4
Basan A, Kissling W, Stefan L.
Valproate as an adjunctive to antipsychotic for schizophrenia: a systematic review
of randomized trials.
Schizophrenia Res.
2004;
70
33-37
- 5
Bersani G, Bressa GM, Meco G, Marini S, Pozzi F.
Combined serotonin 5-HT2 and dopamine D2 antagonist in schizophrenia: clinical, extrapyramidal
and neuroendocrine response in a preliminary study with risperidone (R64766).
Hum Psychopharmacol.
1990;
5
225-231
- 6 Bowers Jr MB, Mazure CM. Studies of the clinical correlates of elevated plasma catecholamine
metabolites. In: Friedhoff AJ, Amin F (eds.):
Plasma homovanillic acid in schizophrenia. Washington, DC: American Psychiatric Press 1997: 17-26
- 7
Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW.
Effect of divalproex combined with olanzapine or risperidone in patients with an acute
exacerbation of schizophrenia.
Neuropsychopharmacol.
2003;
28
182-192
- 8
Castelao JF, Ferreria L, Gelders YG, Heylen SLE.
The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment
of chronic psychosis. An open dose-finding study.
Schizophr Res.
1989;
2
411-415
- 9
Citrome L.
Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital.
J Pharm Technol.
1995;
11
55-59
- 10
Costa E, Grayson DR, Guidotti A.
Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological
intervention?.
Mol Interv.
2003;
3
220-229
- 11
Csernansky JG, Mahmoud R, Brenner R. The risperidone-USA-79 study group .
A comparison of risperidone and haloperidol for the prevention of relapse in patients
with schizophrenia.
New Engl J Med.
2002;
346
16-22
- 12
Gelders YG, Heylen SLE, Vanden BG, Bussche G, Reyntjens AJ, Janssen PAJ.
Pilot clinical investigation of risperidone in the treatment of psychotic patients.
Pharmacopsychiatry.
1990;
23
205-211
- 13
Huang ML, Van Peer A, Woetenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z,
Visscher HW, Jonkman JHG.
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response
in healthy subjects.
Clin Pharmacol Ther.
1993;
54
257-268
- 14
Ichikawa J, Chung Y-C, Dai J, Meltzer HY.
Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal
cortical dopamine release.
Brain Res.
2005;
1052
56-62
- 15
Janssen PAJ, Niemegeers CJF, Awouters F, Schellekens KHL, Megens AAHP, Meert TF.
Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2
antagonistic properties.
J Pharmacol Exp Ther.
1988;
244
1014-1024
- 16
Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K. et al .
Prediction of response to risperidone treatment with respect to plasma concentrations
of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Int Clin Psychopharmacol.
2005;
20
71-78
- 17
Lauterbach EC.
Catatonia-like events after valproic acid with risperidone and sertraline.
Neuropsychiatry Neuropsychol Behav Neurol.
1998;
13
157-163
- 18
Leysen JE, Gommeren W, Eens A, De Chaffog De Coucelles D, Stoof JC, Janssen PAJ.
Biochemical profile of risperidone, a new antipsychotic.
J Pharmacol Exp Ther.
1988;
247
661-670
- 19
Lindenmayer JP, Kotsaftis A.
Use of sodium valproate in violent and aggressive behaviors: a critical review.
J Clin Psychiatry.
2000;
61
123-128
- 20
Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J.
Absorption, metabolism and excretion of risperidone in humans.
Drug Metab Dispos.
1993;
21
1134-1141
- 21
Marder SR, Meibach RC. The Risperidone Study Group .
Risperidone in the treatment of schizophrenia.
Am J Psychiatry.
1994;
151
825-835
- 22
McEvoy JP, Scheifler PL, Frances A.
The expert consensus guideline series: treatment of schizophrenia.
J Clin Psychiatry.
1999;
60
((Suppl))
43
- 23
Meco G, Bedini L, Bonifati V, Sonsinl U.
Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia.
Curr Ther.
1989;
46
876-883
- 24
Minegishi A, Ishizaki T.
Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine
metabolites in plasma by high-performance liquid chromatography with amperometric
detection.
J Chromatgr.
1984;
311
51-57
- 25
Olesen OV, Linnet K.
Simplified high-performance liquid chromatographic method of determination of risperidone
and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic
drugs.
J Chromatogr B.
1997;
698
209-216
- 26
Post RM, Weiss SRB, Chuang DM.
Mechanisms of action of anticonvulsants in affective disorders: comparison with lithium.
J Clin Psychopharmacol.
1992;
12
23-35
- 27
Ravindran A, Silverstone P, Lacroix D, Van Schaick E, Vermeulen A, Alexander J.
Risperidone dose not affect steady-state pharmacokinetics of divalproex sodium in
patients with bipolar disorder.
Clin Pharmacokinet.
2004;
43
733-740
- 28
Rimmer E, Richens A.
An update on sodium valproate.
Pharmacotherapy.
1985;
5
171-184
- 29
Sanders RD, Leher DS.
Edema associated with addition of risperidone to valproate treatment.
J Clin Psychiatry.
1998;
59
689-690
- 30
Scotte A, Janssen PFM, Gommeren W, Luyten WH, Gompel P, Lesage AS.
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo
receptor bindings.
Psychopharmacology.
1996;
124
57-73
- 31
Scordo MG, Spina E, Faccila G, Avenoso A, Johansson I, Dahl ML.
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Psychopharmacology.
1999;
147
300-305
- 32
Spina E, Avenoso A, Facciola G, Salemi M, Scordo M, Giacobello T, Madia A, Perucca E.
Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication
with carbamazepine or valproate.
Ther Drug Monit.
2000;
22
481-485
- 33
Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E.
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and
clinical response in patients with schizophrenia.
Psychopharmacology.
2001;
153
238-243
- 34
Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA.
Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal
cortical gamma-aminobutyric acid neurons in subjects with schizophrenia.
Arch Gen Psychiatry.
2000;
57
237-245
- 35
Volk DW, Lewis DA.
Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction.
Physiol Behav.
2002;
77
501-505
- 36
Wilder BJ.
Pharmacokinetics of valproate and carbamazepine.
J Clin Psychopharmacol.
1992;
2
64-68
- 37
Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A.
Mood stabilizers plus risperidone or placebo in the treatment of acute mania.
Br J Psychiatry.
2003;
182
141-147
- 38
Yeung PKF, Buckley SL, Pedder SCJ, Dingemanse J.
Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in
human plasma by a simple and rapid high-performance liquid chromatography assay.
J Pharm Sci.
1996;
85
451-453
- 39
Yoshimura R, Yanagihara N, Hara K, Terao T, Nakamura J, Ueno S. et al .
Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporters
in cultured bovine adrenal medullary cells.
Psychopharmacology.
2000;
149
17-23
- 40
Yoshimura R, Nakamura J, Ueda N, Terao T.
Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels
in schizophrenic patients: relationship among plasma concentrations of risperidone
and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
Int Clin Psychopharmacol.
2000;
15
175-180
- 41
Yoshimura R, Ueda N, Shinkai K, Nakamura J.
Plasma levels of homovanillic acid and the response to risperidone in first episode
untreated acute schizophrenia.
Int Clin Psychopharmacol.
2003;
18
107-111
- 42
Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K. et al .
An open study of risperidone liquid in the acute phase of schizophrenia.
Hum Psychopharmacol.
2005;
20
243-248
- 43
Yoshimura R, Shinkai K, Kakihra S, Goto M, Yamada Y, Kaji K, Ueda N, Nakamura J.
Little effects of low dosage of levomepro-mazine on plasma risperidone levels.
Pharmacopsychiatry.
2005;
38
98-100
Correspondence
R. Yoshimura
Department of Psychiatry · University of Occupational and Environmental Health
1-1 Iseigaoka
Yahatanishi-ku
Kitakyushu
Fukuoka 8078555
Japan
Phone: +81/936/917 253
Fax: +81/936/924 984
Email: yoshi621@med.uoeh-u.ac.jp
